Incyte Corp (INCY) stock
Close on Nov 13, 2026Market cap $24.66BP/E 64.3Yield –
Incyte Corp grew revenue 24.9% to $6.01B over the twelve months to Sep 30, 2026. Operating income fell 57.7% to $626.51M, moving the operating margin from 30.8% to 10.4%. At the latest close the market valued the company at $24.66B, 64.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $24.66B
- P/E ratio
- 64.3
- Price to sales
- 4.10
- Price to book
- 4.37
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $6.01B
- Net income
- $403.41M
- EPS, diluted
- $1.88
- Book value per share
- $27.76
- Diluted shares
- 203M
Trading
- Next earnings
- Feb 9, 2027 (estimated, before the open)
- Previous close
- $121.70
- Open
- $121.89
- Day's range
- $119.72 – $122.06
- Volume
- 950,508
- Average volume (20 days)
- 1,754,388
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.44
- 52-week range
- $89.25 – $132.60
- RSI (14 days)
- 54.2
- Volatility (1 year)
- 33.1%
- Relative volume
- 0.57×
- WACC
- 7.5%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | INCY | S&P 500 | Difference | INCY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.4% | -3.0% | +14.4 pts | ||
| 3 months | +0.4% | -2.8% | +3.2 pts | ||
| Year to date | +22.5% | +11.5% | +11.0 pts | ||
| 1 year | +14.8% | +13.5% | +1.3 pts | ||
| 3 years | +127.7% | +77.7% | +50.0 pts | +31.6% | +21.1% |
| 5 years | +84.4% | +72.6% | +11.8 pts | +13.0% | +11.5% |
| 10 years | +15.7% | +308.2% | −292.4 pts | +1.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Incyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
About Incyte
Services-Commercial Physical & Biological Research
Incyte is a biopharmaceutical company that discovers, develops, and commercializes therapeutics across hematology, oncology, and inflammation and autoimmunity. Its approved portfolio includes treatments such as Jakafi, Iclusig, Monjuvi, and Niktimvo for hematologic conditions, Pemazyre and Zynyz for oncology indications, and Opzelura cream for inflammatory dermatological conditions. The company distributes its medicines to specialty, retail, and hospital pharmacies, specialty distributors, and pharmaceutical wholesalers.
Company profile, executives and historyIncyte stock: common questions
What is Incyte's stock price?
INCY closed at $120.97 on Nov 13, 2026, down 0.60% on the day. Over the past 52 weeks it traded between $89.25 and $132.60.
What is Incyte's market cap?
Incyte was worth $24.66B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is INCY's P/E ratio?
INCY trades at 64.3 times earnings, based on diluted earnings per share of $1.88 over the twelve months to Sep 30, 2026.
How much revenue does Incyte make?
Incyte reported revenue of $6.01B for the twelve months to Sep 30, 2026, up 24.9% from a year earlier.
Does Incyte pay a dividend?
No. Incyte has not paid a cash dividend over the last twelve months.
When does Incyte report earnings next?
Incyte is expected to report Q4 FY2026 results on Feb 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has INCY stock performed over the past year?
Including dividends, INCY returned +14.8% over the past year, against +13.5% for the S&P 500.
How many INCY shares are sold short?
11M shares were sold short at the latest FINRA report, 7.82% of the float, or 5.6 days of average trading volume.
Who are Incyte's competitors?
Companies most similar to Incyte by business, industry and size include ICLR, CRL, IQV, MEDP, ONC.
See a number that looks wrong?